A Study of ARRY-502 in Patients With Persistent Asthma

Summary

This is a Phase 2 study, involving a 6-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-502 in treating mild to moderate persistent asthma, and to further evaluate the safety of the drug. Approximately 180 patients from the US will be enrolled in this study.

Timeline

Start

2012-04-02

Primary completion

2013-05-31

Completion

2013-06-10

Drugs

Indications